19:54 , May 12, 2017 |  BC Week In Review  |  Clinical News

AZ's tralokinumab misses in Phase III asthma trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said 300 mg tralokinumab (CAT-354) every 2 weeks missed the primary endpoint of reducing annual asthma exacerbation rate in the overall population vs. placebo in the Phase III STRATOS 1 trial...
21:21 , May 10, 2017 |  BC Extra  |  Clinical News

AZ's asthma candidate misses in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in the Phase III STRATOS 1 trial to treat severe uncontrolled asthma. Compared to placebo, the human IgG4 mAb against IL-13 did not significantly...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Lebrikizumab: Phase III data

Top-line data from the identical, double-blind, international Phase III LAVOLTA I and LAVOLTA II trials in >2,100 patients total with severe uncontrolled asthma despite treatment with inhaled corticosteroids and a second controller medication showed that...
02:10 , Mar 1, 2016 |  BC Extra  |  Clinical News

Mixed results for Roche's lebrikizumab in asthma

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said lebrikizumab ( RG3637 ) met the primary endpoint of reducing the rate of asthma exacerbations over 52 weeks vs. placebo in the Phase III LAVOLTA I...
08:00 , Feb 8, 2016 |  BioCentury  |  Product Development

Asthma armament

Amgen Inc .'s AMG 282 could allow Genentech Inc. to treat an asthma patient population not currently covered by its existing pipeline - or by any other targeted therapies in the clinic. The mAb has...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Abbott, AstraZeneca deal

Abbott and AstraZeneca partnered to develop and commercialize companion diagnostics to identify patients with severe asthma most likely to benefit from tralokinumab from AZ’s MedImmune LLC unit. Abbott will develop tests to measure serum levels...
07:00 , Aug 21, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Hepatic disease Periostin (POSTN) Studies in mice and humans suggest inhibiting periostin could help treat hepatosteatosis. In mouse models of obesity and in patients...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

Tralokinumab: Phase IIb data

A double-blind, international Phase IIb trial in 452 patients with uncontrolled, severe asthma showed that subcutaneous tralokinumab every 2 weeks and subcutaneous tralokinumab every 2 weeks for 12 weeks followed by every 4 weeks each...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

Lebrikizumab: Phase IIb data

Pooled data from 463 patients with severe asthma uncontrolled on inhaled corticosteroids and a second controller in the identical, double-blind, U.S. and Australian Phase IIb LUTE and VERSE trials showed that subcutaneous lebrikizumab every 4...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Periostin (POSTN) In vitro and rat studies suggest POSTN could promote axon regeneration after SCI. In cultured...